adhdresearch.news
← Latest research
Paper published Added
PubMed

ADHD Medication Use in Pregnancy Was Not Linked to More Major Birth Defects

Once other differences between mothers were accounted for, taking a stimulant or atomoxetine during pregnancy was not tied to more major birth defects, miscarriage, preterm birth, or autism and ADHD in children. Two small signals remained: a modest rise in heart defects with methylphenidate, and more low newborn health scores at five minutes after birth. The studies can't show these are caused by the medication.

What you can do

If you're pregnant or planning to be, bring these numbers, including the Apgar and methylphenidate findings, to your prescriber and decide together whether to continue, switch, or stop.

Evidence
Study design
meta-analysis
Population
Pregnancies and offspring exposed prenatally to stimulants (methylphenidate- or amphetamine-based) or atomoxetine for ADHD, versus unexposed comparators; 25 studies included, 23 in quantitative analyses
Sample size
25 studies included; 23 contributed to quantitative analyses. Participant numbers not reported in the abstract.
Intervention / exposure
Prenatal exposure to stimulant medications (methylphenidate, amphetamine-based) or atomoxetine; exposure windows included periconceptional, first-trimester, early-, late-, or continued-pregnancy exposure
Comparator
Unexposed pregnancies/offspring; for neurodevelopmental outcomes, comparators restricted to ADHD populations were prioritized when available
Key results
  • Major congenital malformations: Associated in unadjusted analyses (RR 1.25) but not after adjustment (aRR 1.04)
  • Cardiovascular malformations: No adjusted association overall (aRR 1.20); methylphenidate showed a modest increase (aRR 1.33)
  • Miscarriage, preterm birth, low birth weight, small for gestational age, NICU admission: Not associated with exposure in adjusted analyses
  • Neurodevelopmental disorders, autism spectrum disorder, offspring ADHD: Not associated with exposure in adjusted analyses; lower adjusted ASD risk with stimulants was not replicated in methylphenidate-specific analyses
  • Low 5-minute Apgar score: Remained associated with exposure after adjustment (aRR 1.21)
Effect estimates
  • risk ratio: 1.25 · 95% CI 1.14-1.37 · Major congenital malformations, prenatal stimulant/atomoxetine exposure vs unexposed, unadjusted
  • risk ratio: 1.04 (adjusted) · 95% CI 0.97-1.12 · Major congenital malformations, exposed vs unexposed, adjusted
  • risk ratio: 1.20 (adjusted) · 95% CI 0.88-1.63 · Cardiovascular malformations, exposed vs unexposed, adjusted
  • risk ratio: 1.33 (adjusted) · 95% CI 1.01-1.74 · Cardiovascular malformations, methylphenidate exposure vs unexposed, adjusted
  • risk ratio: 1.21 (adjusted) · 95% CI 1.03-1.42 · Low 5-minute Apgar score, exposed vs unexposed, adjusted
Limitations
  • Authors state attenuation of crude associations after adjustment suggests confounding by indication, residual confounding, and maternal characteristics
  • Authors state the methylphenidate-cardiovascular malformation and low 5-minute Apgar associations 'warrant continued investigation but should not be interpreted as evidence of causal harm'
  • Lower adjusted ASD risk with stimulants was not replicated in methylphenidate-specific analyses
  • Abstract-only; heterogeneity, risk-of-bias ratings, and participant numbers are not reported
  • Exposure windows varied across studies (periconceptional to continued pregnancy)
Source reviewed
Abstract
References

Komargodski R, Tillawe A, Berlin M et al. Pregnancy and Offspring Outcomes After Prenatal Stimulant or Atomoxetine Exposure: A Systematic Review and Meta-analysis. American journal of obstetrics & gynecology MFM. 2026-10-16